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Background: The echinocandins are recommended as first-line therapy for Candida species infections, but drug
resistance, especially among Candida glabrata, is becoming more frequent. We investigated the antifungal susceptibility
of anidulafungin, caspofungin, and micafungin against 584 isolates of Candida spp. (bloodstream, other sterile
sites) collected from patients admitted to an Italian university hospital between 2000 and 2013. The susceptibility
was evaluated using the broth microdilution method according to both the European Committee for Antimicrobial
Susceptibility Testing (EUCAST EDef 7.2) and the Clinical Laboratory Standards Institute (CLSI M27-A3). The echinocandin
susceptibilities were assessed on the basis of the species-specific clinical breakpoints proposed by the EUCAST version
6.1 and CLSI M27-S4 documents. The two methods were comparable by assessing essential agreement (EA), categorical
agreement (CA), and Spearman’s correlation analysis (rho, r).
Results: The modal minimum inhibitory concentrations (MICs; μg ⋅ mL −1) values by both methods (EUCAST/CLSI) for
anidulafungin, caspofungin, and micafungin for each species were, respectively, as follows: C. albicans, 0.03/0.12, 0.016/0.5,
and 0.016/0.008; C. parapsilosis complex, 2/1, 2/2, and 2/1; C. tropicalis, 0.06/0.12, 0.06/0.12, and 0.06/0.12; C.
glabrata complex, 0.03/0.25, 0.06/0.12, and 0.03/0.06; C. guilliermondii, 2/1, 2/2, and 2/2; and C. krusei, 0.06/0.12,
0.12/0.5, and 0.06/0.12. The overall resistance rates for EUCAST/CLSI were as follows: anidulafungin, 2.5/0.9 %;
caspofungin, breakpoint not available/3.8 %; micafungin, 2.7/1.5 %.
Candida glabrata complex was the least susceptible to all three echinocandins, and the percentages of resistant
isolates by EUCAST/CLSI were as follows: anidulafungin, 13.5/2.7 %; caspofungin, breakpoint not available/16.2 %;
micafungin, 18.9/13.5 %. The overall EA was 93 % for micafungin, 92 % for anidulafungin, and 90 % for caspofungin.
The CA was >90 % for all organism-drug combinations with the exception of C. glabrata and anidulafungin (89 %).
Spearman’s rho for EUCAST/CLSI was 0.89 (p < 0.001) for caspofungin, 0.85 (p < 0.001) for anidulafungin, and 0.83 for
micafungin (p < 0.001).
Conclusions: Independent of the procedure applied, no alarming resistance to the tested agents was found, although a
reduced susceptibility was detected for C. glabrata complex. The EUCAST and CLSI methods produce similar MICs, indicating
that using one method or the other should not result in susceptibilities different enough to affect treatment decisions.
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The echinocandins (anidulafungin [AND], caspofungin
[CSP], and micafungin [MCF]) are lipopeptides that inhibit
glucan synthase, which is responsible for the biosyn-
thesis of β-1,3-D-glucan, a major structural component
of fungal cell walls. These drugs demonstrate fungicidal
activity against most species of Candida and are effect-
ive against azole-resistant yeasts and Candida-forming
biofilms [1–5]. The Infectious Diseases Society of America
[6] and the European Society of Clinical Microbiology and
Infectious Diseases [7] guidelines for the management of
Candida infection recommend echinocandins for first-
line therapy [8].
Two reference methods analyze the susceptibility of
yeasts to echinocandins: the broth microdilution (BMD)
method designed by the Clinical Laboratory Standards
Institute (CLSI) [9, 10] and the method proposed by the
European Committee for Antimicrobial Susceptibility
Testing (EUCAST) [11–13]. These methods have some
aspects in common: the use of BMD, the use of RPMI
1640 broth as a basal medium, a 24-h incubation period,
and a prominent inhibition (50 % relative to the growth
control) minimum inhibitory concentration (MIC) end-
point criterion. The main differences are as follows: in-
oculum density (CLSI, 0.5 × 103 to 2.5 × 103 cells ⋅ mL−1;
EUCAST, 0.5 × 105 to 2.5 × 105 cells ⋅ mL−1); glucose con-
tent of the medium (CLSI, 0.2 %; EUCAST, 2.0 %);
microdilution wells (CLSI, round-bottom wells; EUCAST,
flat-bottom wells); and endpoint reading (CLSI, visual
reading; EUCAST, spectrophotometric reading). More-
over, EUCAST breakpoints for AND and MCF are lower
than the CLSI breakpoints; additionally, EUCAST has not
proposed clinical breakpoints for CSP.
Until now, in Italy, there is not an extensive study con-
cerning the in vitro susceptibility of echinocandins
against Candida isolates using the EUCAST method
[14]. The aims of this study are: i) to determine the sus-
ceptibilities of Candida spp. to AND, CSP, and MCF
using both the EUCAST and CLSI methods; and ii) to
compare the performance of both methods by assessing
the essential agreement (EA) and categorical agreement
(CA) levels.
Results and discussion
In each experiment, the MIC values of the quality con-
trol strains fell within the established ranges published
for both methods [9, 13]. The modal MIC (μg ⋅ mL − 1;
15 repetitions) values by EUCAST/CLSI for AND, CSP,
and MCF for each control strain were, respectively, as
follows: C. krusei ATCC 6258, 0.06/0.12, 0.5/0.5, and
0.12/0.12; C. parapsilosis ATCC 22019, 1/1, 0.5/1, and
0.5/0.5. Table 1 summarizes the in vitro susceptibility
values of 584 clinical isolates of Candida species to echi-
nocandins as determined by the CLSI and EUCASTBMD methods, as well as EA, and CA between two
methods for each echinocandin and Candida species.
Generally, the MIC values for all three echinocandins
were low and below the susceptibility breakpoint, re-
gardless of the method used. As shown by other authors
[15], the MIC values for AND (geometric mean MIC
EUCAST/CLSI, 0.16/0.22 μg ⋅ mL−1) and MCF (geomet-
ric mean MIC EUCAST/CLSI, 0.13/0.14 μg ⋅ mL−1)
were lower those for CSP (geometric mean MIC
EUCAST/CLSI, 0.29/0.33 μg ⋅ mL−1) by both assay, sug-
gesting that they have superior in vitro potency. When
the species-specific clinical breakpoints were applied, the
overall resistance rates for EUCAST/CLSI were as fol-
lows: AND, 2.5/0.9 %; CSP, breakpoint not available/
3.8 %; MCF, 2.7/1.5 %. These data are consistent with
those reported previously [14, 16–18] and document the
excellent potency and spectrum of echinocandins against
most Candida spp. Of the 22 CSP resistant isolates by
CLSI, five were MCF resistant, three were AND resist-
ant, and one was resistant both AND and MCF; this dis-
crepant susceptibility pattern is according to other
studies [17, 19]. Given the mechanism of action that is
shared among the echinocandins, it is biologically un-
likely that such large percentages of isolates are non sus-
ceptible to CSP but remain susceptible to AND and
MCF. A potential explanation for this finding may be
the technical issues associated with the in vitro testing of
CSP rather than a true difference in antifungal activity
[20]. For this reason, neither EUCAST nor CLSI proce-
dures recommend the use of CSP for antifungal suscep-
tibility testing, while AND and MCF as markers for CSP
susceptibility [11, 21].
The trend in the rate of resistance to echinocandins
was analyzed: no significant trend was observed for each
drug over the studied 14-year period, by both methods.
The MIC values were the highest for C. parapsilosis
complex and C. guilliermondii by the two methods. A
natural polymorphism occurring in the hot spot, one re-
gion of FKS1 has been suggested to be responsible for
the reduced echinocandin susceptibilities of these spe-
cies [22]. Unlike yeasts with acquired FKS mutations,
these strains respond well to standard therapy presum-
ably because the polymorphism only weakly affects the
sensitivity of glucan synthase for drug [5]. Moreover, the
good clinical response of C. parapsilosis may be due to
its less virulent, reduced capacity to invade the deep tis-
sue, and the high probability of therapeutic success if
central venous catheter is removed [15].
In our study, the resistance to AND (EUCAST/CLSI,
13.5/2.7 %), CSP (EUCAST/CLSI, breakpoint not avail-
able/16.2 %), and MCF (EUCAST/CLSI, 18.9/13.5 %)
was most prominent among C. glabrata complex iso-
lates. Similarly, the SENTRY Antimicrobial Surveillance
Program reported echinocandin resistance of 8.0–9.3 %
Table 1 Agreement between the results of the European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory














(%)Range Mode GM MIC90
C. albicans (251) Anidulafungin CLSI ≤0.008–2 0.12 0.03 0.12 246(98) 2(0.8) 3(1.2) 90 99
EUCAST ≤0.008–2 0.03 0.02 0.03 247(98.4) NA 4(1.6)
Micafungin CLSI ≤0.008–1 0.008 0.01 0.12 241(96) 7(2.8) 3(1.2) 92 98
EUCAST ≤0.008–0.5 0.016 0.01 0.016 244(97.2) NA 7(2.8)
Caspofungin CLSI ≤0.008–4 0.5 0.17 0.5 180(71.7) 63(25.1) 8(3.2) 87 NA
EUCAST ≤0.008–2 0.016 0.13 0.5 − − −
C. parapsilosis
complex (224)
Anidulafungin CLSI 0.03–2 1 1.14 2 224(100) 0 0 96 100
EUCAST 0.06–2 2 1.78 2 0 224(100) 0
Micafungin CLSI 0.016–2 1 0.96 2 224(100) 0 0 95 100
EUCAST 0.016–2 2 1.62 2 0 224(100) 0
Caspofungin CLSI 0.25–8 2 1.62 2 217(96.9) 6(2.7) 1(0.4) 98 NA
EUCAST 0.06–8 2 1.82 2 − − −
C. tropicalis (46) Anidulafungin CLSI ≤0.008–1 0.12 0.09 0.25 45(97.8) 0 1(2.2) 91 93
EUCAST ≤0.008–0.25 0.06 0.05 0.06 42(91.3) NA 4(8.7)
Micafungin CLSI ≤0.008–1 0.12 0.07 0.5 37(80.4) (17.4) 1(2.2) 91 NA
EUCAST 0.016–2 0.06 0.11 0.5 − − −
Caspofungin CLSI ≤0.008–2 0.12 0.12 1 34(74) 6(13) 6(13) 89 NA
EUCAST ≤0.008–2 0.06 0.11 1 − − −
C. glabrata
complex (37)
Anidulafungin CLSI ≤0.008–4 0.25 0.13 0.25 24(64.9) 12(32.4) 1(2.7) 72 89
EUCAST ≤0.008–2 0.03 0.06 0.12 32(86.5) NA 5(13.5)
Micafungin CLSI ≤0.008–1 0.06 0.06 0.12 28(75.7) 4(10.8) 5(13.5) 83 95
EUCAST ≤0.008–2 0.03 0.05 0.12 30(81.1) NA 7(18.9)
Caspofungin CLSI ≤0.008–4 0.12 0.18 1 21(56.8) 10(27) 6(16.2) 80 NA
EUCAST ≤0.008–2 0.06 0.17 2 − − −
C. guilliermondii (15) Anidulafungin CLSI 1–2 1 1.45 2 14(93.3) 1(6.7) 0 100 NA
EUCAST 1–2 2 1.91 2 − − −
Micafungin CLSI 0.5–2 2 1.45 2 15(100) 0 0 100 NA
EUCAST 0.5–2 2 1.52 2 − − −
Caspofungin CLSI 0.12–4 2 1.74 2 14(93.3) 1(6.7) 0 93 NA
EUCAST 1–2 2 1.74 2 − − −
C. krusei (11) Anidulafungin CLSI 0.12–0.5 0.12 0.14 0.12 10(90.9) 1(9) 0 90 91
EUCAST 0.06–0.12 0.06 0.06 0.06 10(90.9) NA 1(9.1)
Micafungin CLSI 0.06–0.5 0.12 0.13 0.12 11(100) 0 0 100 NA
EUCAST 0.03–0.5 0.06 0.08 0.25 − − −
Caspofungin CLSI 0.12–2 0.5 0.44 2 6(54.5) 4(36.4) 1(9.1) 90 NA
EUCAST 0.06–2 0.12 0.23 1 − − −
“−” denotes that no breakpoints have yet been established; BMD, broth microdilution; CLSI, Clinical and Laboratory Standards Institute; EUCAST, European
Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration; GM, geometric mean; EA, essential agreement; CA, categorial
agreement; NA, Not applicable; S, susceptible; I, intermediate; R, resistant
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[23]; moreover, in a 10-year survey at the Duke univer-
sity hospital echinocandin resistance rate increased from
4.9 to 12.3 % in 2001–2010 [24]. Prolonged therapy with
these drugs has been suggested to be a potential causefor decreased susceptibility to echinocandins among iso-
lates of C. glabrata [22–27].
A decrease in the activity of AND (EUCAST/CLSI,
8.7/2.2 %), MCF (EUCAST/CLSI, breakpoint not avail-
able/2.2 %), and CSP (EUCAST/CLSI, breakpoint not
Montagna et al. BMC Microbiology  (2015) 15:106 Page 4 of 6available/13 %) was also observed among isolates of C.
tropicalis.
For most isolates, the echinocandin MICs obtained by
the EUCAST method tended to be one twofold dilution
lower than those obtained by the CLSI method. The rea-
son for this result could be related to known differences
between the two methods: the higher carbohydrate con-
tent in the RPMI and higher inoculum could be respon-
sible for the lowering of the EUCAST results [28].
The overall EA was very high: 93 % for MCF, 92 % for
AND, and 90 % for CSP. The Spearman’s correlation
analysis shows a significant positive correlation between
EUCAST and CLSI MICs (r = 0.85, p < 0.001 for AND; r
= 0.89, p < 0.001 for CSP; r = 0.8, p < 0.001 for MCF).
This finding was consistent with the results of previous
global multicenter studies by Pfaller et al. [29, 30] and
confirms the high level of EA between the reference pro-
cedures. The rates of EA were also high when results
were analyzed per species, and the worst EA (72 %) was
for C. glabrata complex tested against AND. A good CA
was also observed for all organism-drug combinations,
ranging from 89 to 100 %. The lowest CA was for C.
glabrata complex isolates to AND, where five (13.5 %)
isolates were resistant when applying EUCAST break-
points as opposed to one (2.7 %) when applying the
CLSI breakpoints. The meaning of this in vitro finding is
not clear and needs to be clarified in more detail. The
best CA was for C. parapsilosis complex to AND and
MCF.
Conclusions
Our study had some limitations. First, none of our
strains were characterized with respect to echinocandin
resistance mechanisms. Second, the lack of EUCAST
species-specific breakpoints for CSP precludes a more
standard comparison for the assessment of the CA.
Third, this study was an observational laboratory based
survey, therefore no data was available as to the type
and duration of antifungal therapy. Nevertheless, to the
best of our knowledge, this is the first study on this topic
to be carried out in Italy. Our data show that the
EUCAST and CLSI echinocandin MIC values for Can-
dida isolates from patients in Italy are in accordance
with the worldwide epidemiology of Candida strains
[14, 16–18]. Likewise, the echinocandins were active
in vitro against the majority of Candida species tested in
this study; a reduced susceptibility, as has been noted
elsewhere [23, 24], was detected for C. glabrata complex
and C. tropicalis. MIC values obtained by the CLSI and
EUCAST methods are comparable for the testing of
echinocandins against Candida species. Regression ana-
lysis confirms the close proximity of the MICs generated
by each method. In most cases, the MIC differences be-
tween standard procedures are small enough that usingone method or the other should not result in susceptibil-
ities that are different enough to affect treatment decisions.
The clinical implications regarding the improvement of
the susceptibility tests to echinocandins are significant,
since accurate data are important in defining differences in
clinical efficacy among AND, CSP and MCF, thereby sup-
porting the most appropriate choice of early antifungal
treatment towards a better prognosis. Further efforts are
needed to harmonize the two standard procedures.
Methods
Clinical isolates
Between January 2000 and December 2013, a total of
597 clinical isolates of Candida spp. (bloodstream and
other sterile sites) were collected from patients admitted
to a large Italian university hospital. Of these, the six
most common Candida species were tested against echi-
nocandins (251 C. albicans, 224 C. parapsilosis, 46 C. tro-
picalis, 37 C. glabrata, 15 C. guilliermondii, 11 C. krusei),
for a total of 584 isolates recovered from the following
wards: intensive care unit (n = 288), haematology (n = 99),
internal medicine (n = 88), surgery (n = 85), and oncology
(n = 24). For this study, we did not use any additional data
or samples other than those obtained through routine la-
boratory collection. Therefore, neither ethical approval
nor patient consent was considered necessary. Registered
data were managed in accordance with the Italian data
protection laws (privacy law). The isolates were identified
using standard procedures (i.e., morphology on cornmeal
agar plates, germ-tube production in serum, and ability
to grow at 37 °C and 42 °C) and biochemical analysis
using the ID32C and VITEK-2 System (Biomérieux,
Marcy l’Etoile, France). Each isolate represented a unique
strain from a single patient and was frozen at −80 °C until
the analysis. Prior to being tested, each isolate was sub-
cultured on Sabouraud dextrose agar plates (BioMèrieux)
to ensure purity, viability, and optimal growth
characteristics.
Susceptibility testing
AND (Pfizer Pharmaceuticals, Groton, CT, USA), CSP
(Merck & Co., Inc., Whitehouse Station, NJ, USA), and
MCF (Astellas Pharma, Tokyo, Japan) were obtained as
standard powders. A single lot of pure substance for
each of the three echinocandins was used. Stock solu-
tions were prepared in dimethyl sulfoxide (Sigma, St.
Louis, MO, USA) for each echinocandin, taking into ac-
count the potencies of the powders.
CLSI BMD testing was performed according to docu-
ment M27-A3 [9, 10] using RPMI 1640 medium with
0.2 % glucose (Sigma) and 0.165 M MOPS, an inoculum
of 0.5 × 103 to 2.5 × 103 cells ⋅ mL−1, and incubation at
35 °C. The MIC values were determined visually after
24 h of incubation as the lowest concentration of drug
Table 2 CLSI (document M27-S4) and EUCAST (version 6.1)
antifungal breakpoints for Candida species
MIC (μg/ml) breakpoint for susceptibility/resistance
Species Anidulafungin Caspofungin Micafungin
C. albicans
CLSI ≤0.25/≥1 ≤0.25/≥1 ≤0.25/≥1
EUCAST ≤0.03/>0.03 − ≤0.016/>0.016
C. parapsilosis
CLSI ≤2/≥8 ≤2/≥8 ≤2/≥8
EUCAST ≤0.002/>4 − ≤0.002/>2
C. glabrata
CLSI ≤0.12/≥0.5 ≤0.12/≥0.5 ≤0.06/≥0.25
EUCAST ≤0.06/>0.06 − ≤0.03/>0.03
C. tropicalis
CLSI ≤0.25/≥1 ≤0.25/≥1 ≤0.25/≥1
EUCAST ≤0.06/>0.06 − −
C. gulliermondii
CLSI ≤2/≥8 ≤2/≥8 ≤2/≥8
EUCAST − − −
C. krusei
CLSI ≤0.25/≥1 ≤0.25/≥1 ≤0.25/≥1
EUCAST ≤0.06/>0.06 − −
“−” denotes that no breakpoints have yet been established
Montagna et al. BMC Microbiology  (2015) 15:106 Page 5 of 6that caused a significant diminution (≥50 % inhibition)
of growth below control levels.
EUCAST BMD testing was performed according to
document EDef 7.2 [available on the EUCAST website:
http://www.eucast.org] using RPMI 1640 medium sup-
plemented with glucose to a final concentration of 2 %,
an inoculum of 0.5 × 105 to 2.5 × 105 cells ⋅ mL − 1, and
incubation at 35 °C. MIC values were determined with a
spectrophotometer (wavelength of 450 nm; ETI System
Fast Reader ELX, Biotek, US) after 24 h of incubation as
the lowest concentration of drug that resulted in >50 % in-
hibition of growth relative to that of the growth control.
C. krusei ATCC 6258 and C. parapsilosis ATCC 22019
were used as quality control strains in each run accord-
ing to the CLSI M27-A3 document [9].Interpretation and analysis of results
The echinocandin susceptibilities were defined according
to the species-specific clinical breakpoints proposed by
the EUCAST version 6.1 [31] and CLSI M27-S4 docu-
ments [10] (Table 2). Differences in the temporal suscep-
tibility rates were analysed by chi-square test for trend.
MIC discrepancies of no more than ± 2-fold dilutions
were used to calculate the EA. The CA was defined as
the percentage of the discrepancy in the number of re-
sistant isolates based on the existence of interpretativebreakpoints [16]. Moreover, to determine the correlation
between the methods, Spearman’s rank correlation coef-
ficient (rho, r), and its corresponding p value was per-
formed by plotting EUCAST versus CLSI MICs. The
level of significance was set at a p value less than 0.05.
Statistical analysis of data was carried out using STATA
MP 11.2 for Mac Os X (SPSS Inc., Chicago, IL, USA).
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